Botelho et al. (2020)BOTELHO PB, FERREIRA MVR, DE MESQUITA ARAÚJO A, MENDES MM & NAKANO EY. 2020. Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: a double-blind, placebo-controlled randomized trial. Nutrition 78: 110890.
|
27/55 (86%) 19 – 43 years Brazil |
L. acidophilus NCFM, L. casei Lc-11, Lc. lactis Li-23, B. bifidum BB-06 and B. lactis HN019 (5 x 109 CFU) in capsules |
Randomized, double-blind, placebo-controlled and parallel (30 days) |
16S rRNA (regions V3-V4) sequencing on Illumina MiSeq platform |
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, Fusobacteria, Synergistetes, Verrucomicrobia, Euryarchaeota and Firmicutes/Bacteroidetes |
Ford et al. (2020)FORD AL, NAGULESAPILLAI V, PIANO A, AUGER J, GIRARD SA, CHRISTMAN M, TOMPKINS TA & DAHL WJ. 2020. Microbiota stability and gastrointestinal tolerance in response to a high-protein diet with and without a prebiotic, probiotic, and synbiotic: a randomized, double-blind, placebo-controlled trial in older women. J Acad Nutr Diet 120(4): 500-516.
|
26/26 (100%) 68 – 79 years EUA |
B. bifidum HA-132 (1.54 x 109 viable cells), B. breve HA-129 (4.62 x 109 viable cells), B. longum HA-135 (4.62 x 109 viable cells), L. acidophilus HA-122 (4.62 x 109 viable cells) and L. plantarum HA-119 (4.62 x 109 viable cells) in capsules |
Randomized, double-blind, placebo-controlled and crossover (18 weeks) |
16S rRNA (region V4) sequencing on Illumina MiSeq platform |
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota, Tenericutes, Verrucomicrobia, Cyanobacteria, Synergistetes and Fusobacteria |
Liu et al. (2020)LIU S, LIU H, CHEN L, LIANG SS, SHI K, MENG W, XUE J, HE Q & JIANG H. 2020. Effect of probiotics on the intestinal microbiota of hemodialysis patients: a randomized trial. Eur J Nutr 59(8): 3755-3766.
|
25/50 (47%) 38 – 58 years China |
B. longum NQ1501 (2.2 x 109 CFU), L. acidophilus YIT2004 (0.53 x 109 CFU) and E. faecalis YIT0072 (1.1 x 109 CFU) in capsules |
Randomized, double-blind, placebo-controlled and parallel (6 months) |
16S rRNA (regions V3-V4) sequencing on Illumina MiSeq platform |
Firmicutes, Bacteroidetes and Bacteroidetes/ Firmicutes |
Song et al. (2020) SONG E J, HAN K, LIM TJ, LIM S, CHUNG M J, NAM M H, KIM H & NAM Y. 2020. Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial. EPMA J 11(1): 31-51.
|
25/50 (84%) 34 – 54 years Korea |
B. breve and L. plantarum CBT LP3 (15 x 109 viable cells) in capsules |
Randomized, double-blind, placebo-controlled and parallel (12 weeks) |
16S rRNA (regions V3-V4) sequencing on Illumina MiSeq platform |
Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, Fusobacteria and others |
Wu et al. (2020)WU, J, GAN T, ZHANG Y, XIA G, DENG S, LV X, ZHANG B & LV B. 2020. The prophylactic effects of BIFICO on the antibiotic-induced gut dysbiosis and gut microbiota. Gut Pathog 12(1): 1-11.
|
64/131 (45%) 46 – 80 years China |
B. longum, L. acidophilus and E. faecalis (1 x 109 CFU/g) in capsules |
Randomized, open-label, placebo-controlled and prospective (2 weeks) |
16S rRNA amplicon sequencing |
Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, Fusobacteria and others |
Francavilla et al. (2019)FRANCAVILLA R ET AL. 2019. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol 53(3): e117.
|
55/109 (86%) 18 – 62 years Italy |
L. casei LMG 101/37 P-17504 (5 x 109 CFU), L. plantarum CECT 4528 (5 x 109 CFU), B. animalis subsp. lactis Bi1 LMG P-17502 (10 x 109 CFU), B. breve Bbr8 LMG P-17501 (10 x 109 CFU) e B. breve Bl10 LMG P-17500 (10 x 109 CFU) in power |
Randomized, double-blind, placebo-controlled and parallel (6 weeks) |
16S-based (region V3) pyrosequencing |
Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria and Fusobacteria |
Martoni et al. (2019)MARTONI CJ, EVANS M, CHOW CET, CHAN LS & LEYER G. 2019. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: a randomized controlled trial. J Dig Dis 20(9): 435-446.
|
47/93 (53%) 29 – 57 years Canada |
L. acidophilus, B. animalis subsp. lactis, B. longum and B. bifidum (1.5 × 1010 CFU) in capsules |
Randomized, double-blind, placebo-controlled and parallel (4 weeks) |
16S rRNA (region V4) sequencing on Illumina MiSeq platform |
Firmicutes, Actinobacteria, Bacteroides, Euryarcharota, Verrumicrobiota, Proteobacteria and Tenericutes |
Plaza-Díaz et al. (2015) |
4/9 (44%) 20 – 30 years Spain |
B. breve CNCM I-4035 and L. rhamnosus CNCM I-4036 (9 x 109 CFU) in capsules |
Randomized, double-blind, placebo-controlled and parallel (30 days) |
16S rRNA (regions V1-V3) pyrosequencing |
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria and others |